Retinitis Pigmentosa Clinical Trial
Official title:
Modulating Ocular/Retinal Blood Flow and Visual Function in Retinitis Pigmentosa
Verified date | June 2023 |
Source | Nova Southeastern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Measures of vision in RP patients receiving promising therapy using transcorneal electrical stimulation.
Status | Active, not recruiting |
Enrollment | 21 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age 18+ - Diagnosis of retinitis pigmentosa (RP) - Best-corrected visual acuity better than 20/400 in at least one eye - More than 20% loss of Goldmann Visual Field area (III4e test target) in at least one eye - Able and willing to participate in all study visits for a ~4-6 month period - Provide informed consent Exclusion Criteria: - Very severe vision losses in both eyes (e.g., hand motions or light perception only) with difficulty performing the proposed vision tests - Vision loss due to ocular diseases other than RP, cystoid macular edema, or cataracts - Schedules do not permit participation in all study visits - Previous acupuncture or TES treatment for RP - Inability to understand study procedures or communicate responses to visual stimuli in a consistent manner (cognitive impairment) - Dementia; Long or short-term memory loss - Unable to read or speak English - Smoking, excessive alcohol, or illegal drug use - Receiving current psychiatric care (i.e. unstable emotional and mental health status) - History of excessive bleeding - Reduced general health and/or systemic medications that may diminish the potential response to the electroacupuncture treatments - Implanted cardiac pacemaker - Pregnancy |
Country | Name | City | State |
---|---|---|---|
United States | Nova Southeastern University; College of Optometry | Fort Lauderdale | Florida |
Lead Sponsor | Collaborator |
---|---|
Nova Southeastern University | National Eye Institute (NEI) |
United States,
Bittner AK, Gould JM, Rosenfarb A, Rozanski C, Dagnelie G. A pilot study of an acupuncture protocol to improve visual function in retinitis pigmentosa patients. Clin Exp Optom. 2014 May;97(3):240-7. doi: 10.1111/cxo.12117. Epub 2013 Oct 29. — View Citation
Bittner AK, Seger K, Salveson R, Kayser S, Morrison N, Vargas P, Mendelsohn D, Han J, Bi H, Dagnelie G, Benavente A, Ramella-Roman J. Randomized controlled trial of electro-stimulation therapies to modulate retinal blood flow and visual function in retini — View Citation
Bittner AK, Seger K. Longevity of visual improvements following transcorneal electrical stimulation and efficacy of retreatment in three individuals with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2018 Feb;256(2):299-306. doi: 10.1007/s00417- — View Citation
Kayser S, Vargas P, Mendelsohn D, Han J, Bi H, Benavente A, Bittner AK. Reduced Central Retinal Artery Blood Flow Is Related to Impaired Central Visual Function in Retinitis Pigmentosa Patients. Curr Eye Res. 2017 Nov;42(11):1503-1510. doi: 10.1080/027136 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Significant changes from baseline in Goldmann visual field area in both eyes | Using Haig-Streit Octopus perimeter | twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation | |
Secondary | Significant changes from baseline in best-corrected ETDRS visual acuity at both 2 weeks and 6 weeks post-intervention initiation | Using Pelli-Robson visual acuity charts | twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation | |
Secondary | Changes in Macular edema Optical Coherence Tomography (OCT) | Using Optical Coherence Tomography | twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation | |
Secondary | Significant changes from baseline in contrast sensitivity at both 2 weeks and 6 weeks post-intervention initiation | Using Adaptive Sensory Technology Quick CSF | twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation | |
Secondary | Significant changes from baseline in Dark adaptation function at both 2 weeks and 6 weeks post-intervention initiation | Using the AdaptDx by Maculogix | twice at baseline, then 2 weeks, 6 weeks and 12 weeks post-intervention initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01432847 -
Cell Collection to Study Eye Diseases
|
||
Completed |
NCT04983914 -
Retrospective NIS to Evaluate the Patient Benefit of TES
|
||
Recruiting |
NCT03845218 -
Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures
|
||
Completed |
NCT00231010 -
Molecular Genetics of Retinal Degenerations
|
||
Active, not recruiting |
NCT04611503 -
PDE6A Gene Therapy for Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Recruiting |
NCT01914913 -
Clinical Study to Evaluate Safety and Efficacy of BMMNC in Retinitis Pigmentosa
|
Phase 1/Phase 2 | |
Completed |
NCT01949623 -
Biomarkers In Retinitis Pigmentosa (BIRP)
|
N/A | |
Completed |
NCT01835002 -
Transcorneal Electrical Stimulation - Multicenter Safety Study
|
N/A | |
Completed |
NCT00407602 -
Argus® II Retinal Stimulation System Feasibility Protocol
|
N/A | |
Completed |
NCT00515814 -
Retina Implant Pilot Trial to Evaluate Safety & Efficacy in Blind Patients Having Degenerated Photo-receptors
|
N/A | |
Completed |
NCT00100230 -
DHA and X-Linked Retinitis Pigmentosa
|
Phase 2 | |
Active, not recruiting |
NCT00378742 -
Repository for Inherited Eye Diseases
|
||
Terminated |
NCT05085964 -
An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa
|
Phase 2 | |
Recruiting |
NCT05805007 -
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
|
Early Phase 1 | |
Recruiting |
NCT05909488 -
Role of UC-MSC and CM to Inhibit Vision Loss in Retinitis Pigmentosa Phase I/II
|
Phase 2/Phase 3 | |
Recruiting |
NCT06291935 -
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
|
Phase 1 | |
Recruiting |
NCT03078309 -
The Effects of Cannabis on Visual Functions in Healthy and Retinitis Pigmentosa Patients
|
Early Phase 1 | |
Completed |
NCT04238858 -
Effects of Subtenon-injected Autologous Platelet-rich Plasma on Visual Functions in Eyes With Retinitis Pigmentosa
|
N/A | |
Active, not recruiting |
NCT01680510 -
The Effect of Oral Administration of 9-cis β Carotene Rich Powder of the Alga Dunaliella Bardawil
|
Phase 1/Phase 2 |